Bioverativ Inc (NASDAQ:BIVV) has been assigned a consensus recommendation of “Buy” from the twelve analysts that are presently covering the company. Two investment analysts have rated the stock with a sell rating, three have given a hold rating, six have issued a buy rating and one has issued a strong buy rating on the company. The average 1-year price objective among brokerages that have issued a report on the stock in the last year is $54.18.
A number of equities research analysts recently commented on the stock. Cowen and Company reiterated a “market perform” rating and set a $47.00 price target on shares of Bioverativ in a report on Wednesday, February 8th. Argus initiated coverage on shares of Bioverativ in a research report on Friday, March 31st. They set a “hold” rating and a $51.00 price objective on the stock. Gabelli reissued a “buy” rating on shares of Bioverativ in a research report on Thursday, February 2nd. Leerink Swann initiated coverage on shares of Bioverativ in a research report on Wednesday, February 15th. They set an “outperform” rating and a $56.00 price objective on the stock. Finally, Jefferies Group LLC reissued a “buy” rating and set a $53.00 price objective on shares of Bioverativ in a research report on Tuesday, April 4th.
Bioverativ (NASDAQ:BIVV) traded down 0.76% on Monday, hitting $57.18. 691,398 shares of the stock were exchanged. The company has a 50-day moving average price of $53.26 and a 200 day moving average price of $50.86. The company has a market capitalization of $6.17 billion and a PE ratio of 14.05. Bioverativ has a 1-year low of $40.00 and a 1-year high of $58.29.
Bioverativ Company Profile
Bioverativ Inc (Bioverativ) is a biotechnology company. The Company is focused on the discovery, research, development and commercialization of therapies for the treatment of hemophilia and other blood disorders. It markets approximately two products, including ELOCTATE [Antihemophilic Factor (Recombinant), Fc Fusion Protein], and ALPROLIX [Coagulation Factor IX (Recombinant), Fc Fusion Protein], extended half-life clotting-factor therapies for the treatment of hemophilia A and hemophilia B, respectively.
What are top analysts saying about Bioverativ Inc? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Bioverativ Inc and related companies.